| Literature DB >> 33269405 |
Carlos Pelayo Hernández-Fernández1, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Esteban Daudén, Pablo de Cueva, Isabel Belinchón, Francisco Javier Gómez-García, Enrique Herrera-Acosta, Diana P Ruiz-Genao, Marta Ferrán, Mercé Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Rafael Botella-Estrada, Antonio Sahuquillo-Torralba, Lourdes Rodríguez, Jaime Vilar-Alejo, Carmen García-Donoso, José M Carrascosa, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Jose Luis López-Estebaranz, Conrad Pujol-Marco, Miguel Angel Descalzo, Ignacio Garcia-Doval.
Abstract
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.Entities:
Keywords: biological therapy; drug prescription; drug safety; gender bias; psoriasis; sex; sex bias; gender
Mesh：
Substances：
Year: 2021 PMID： 33269405 PMCID： PMC9309850 DOI： 10.2340/00015555-3711
Source DB: PubMed Journal: Acta Derm Venereol ISSN： 0001-5555 Impact factor: 3.875